Glenn S Tillotson

Summary

Publications

  1. doi Antibiotic resistance: the challenge from an industry perspective
    Glenn S Tillotson
    Head of Medical Affairs, ViroPharma Incorporated, Exton, PA, USA
    Expert Rev Clin Pharmacol 2:119-23. 2009
  2. doi Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective
    Glenn S Tillotson
    Replidyne, Milford, Connecticut, USA
    Clin Infect Dis 47:S237-40. 2008
  3. doi Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective
    Roger M Echols
    Replidyne, Inc, Louisville, Colorado, USA
    Clin Infect Dis 47:S166-75. 2008
  4. pmc National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study
    Ian A Critchley
    Replidyne, Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 51:4382-9. 2007
  5. ncbi Meeting report: Fourth Forum on Respiratory Tract Infections, Sitges, Spain, 8 11 February 2007
    Glenn S Tillotson
    Replidyne Inc, Milford, CT, USA
    J Antimicrob Chemother 60:464-9. 2007
  6. ncbi Antibiotic development: a victim of market forces?
    Glenn S Tillotson
    Replidyne Inc, 472 Wheelers Farms Road, 3rd Floor, Milford, CT 06461, USA
    IDrugs 11:340-6. 2008
  7. ncbi Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?
    Glenn S Tillotson
    Replidyne Inc, 472 Wheelers Farms Rd, Milford, CT 06460, USA
    Expert Rev Anti Infect Ther 5:53-9. 2007

Detail Information

Publications7

  1. doi Antibiotic resistance: the challenge from an industry perspective
    Glenn S Tillotson
    Head of Medical Affairs, ViroPharma Incorporated, Exton, PA, USA
    Expert Rev Clin Pharmacol 2:119-23. 2009
    ..Here, he talks with Expert Review of Clinical Pharmacology about the challenge of antibiotic resistance from an industry perspective. ..
  2. doi Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective
    Glenn S Tillotson
    Replidyne, Milford, Connecticut, USA
    Clin Infect Dis 47:S237-40. 2008
    ..We discuss the underlying issues and offer some alternative strategies to enable improvements in clinical trial design for community-acquired pneumonia...
  3. doi Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective
    Roger M Echols
    Replidyne, Inc, Louisville, Colorado, USA
    Clin Infect Dis 47:S166-75. 2008
    ....
  4. pmc National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study
    Ian A Critchley
    Replidyne, Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 51:4382-9. 2007
    ..5 mug/ml for S. pneumoniae, 1 mug/ml for H. influenzae, and 0.5 mug/ml for M. catarrhalis, suggesting that faropenem shows promise as a treatment option for respiratory infections caused by contemporary resistant phenotypes...
  5. ncbi Meeting report: Fourth Forum on Respiratory Tract Infections, Sitges, Spain, 8 11 February 2007
    Glenn S Tillotson
    Replidyne Inc, Milford, CT, USA
    J Antimicrob Chemother 60:464-9. 2007
    ..The entire meeting was granted CME recognition (18 sessions) by the European Accreditation Council for continuing medical education...
  6. ncbi Antibiotic development: a victim of market forces?
    Glenn S Tillotson
    Replidyne Inc, 472 Wheelers Farms Road, 3rd Floor, Milford, CT 06461, USA
    IDrugs 11:340-6. 2008
    ..This feature review addresses some of the factors that have played a role in the current paucity of new antibiotics under development, and discusses the dangerous repercussions if major changes are not implemented soon...
  7. ncbi Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?
    Glenn S Tillotson
    Replidyne Inc, 472 Wheelers Farms Rd, Milford, CT 06460, USA
    Expert Rev Anti Infect Ther 5:53-9. 2007
    ..This inexorable increase is occurring in the face of a dearth of new antibiotics for community use and even fewer for treating resistant nosocomial gram-negative species. The possible strategies and consequences are discussed...